Get the Stockscreener App
10.08
15.33%
1.34
After Hours:
10.06
-0.02
-0.20%
Ginkgo Bioworks Holdings Inc stock is traded at $10.08, with a volume of 2.71M.
It is up +15.33% in the last 24 hours and up +58.49% over the past month.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.
See More
Previous Close:
$8.74
Open:
$8.46
24h Volume:
2.71M
Relative Volume:
2.20
Market Cap:
$579.39M
Revenue:
$217.11M
Net Income/Loss:
$-651.19M
P/E Ratio:
-14.20
EPS:
-0.71
Net Cash Flow:
$-387.26M
1W Performance:
+6.78%
1M Performance:
+58.49%
6M Performance:
-38.34%
1Y Performance:
-85.18%
1-Day Range:
$8.40
$10.53
1-Week Range:
$8.40
$10.53
52-Week Range:
$5.26
$74.00
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Name
Ginkgo Bioworks Holdings Inc
Sector
Industry
Phone
(877) 442-5362
Address
27 DRYDOCK AVENUE, BOSTON
Compare DNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
10.08 | 579.39M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-24 | Downgrade | BTIG Research | Neutral → Sell |
| May-10-24 | Downgrade | William Blair | Mkt Perform → Underperform |
| Nov-14-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-09-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-02-23 | Downgrade | Goldman | Neutral → Sell |
| May-11-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-29-22 | Initiated | Berenberg | Buy |
| Oct-04-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Feb-23-22 | Initiated | Goldman | Neutral |
| Feb-01-22 | Initiated | BofA Securities | Neutral |
| Jan-28-22 | Initiated | BofA Securities | Buy |
| Jan-07-22 | Initiated | BTIG Research | Buy |
| Nov-29-21 | Initiated | Jefferies | Buy |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Oct-12-21 | Initiated | William Blair | Outperform |
| Sep-20-21 | Initiated | HSBC Securities | Buy |
View All
Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News
Ginkgo Bioworks (NYSE:DNA) Stock Price Up 4.1%Time to Buy? - MarketBeat
Teachers Retirement System of The State of Kentucky Cuts Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to Buy - MSN
Ginkgo Bioworks joins project on cell-based disease treatment By Investing.com - Investing.com South Africa
Ginkgo Bioworks joins project on cell-based disease treatment - Investing.com
Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program - PR Newswire
Charles Schwab Investment Management Inc. Decreases Stock Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks Investors Get Final OK Of $17.8M Settlement - Law360
Janus Henderson Group PLC Has $118,000 Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Trading Down 5.5%What's Next? - MarketBeat
Verition Fund Management LLC Takes Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Lowers Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
BNP Paribas Financial Markets Makes New Investment in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Long Term Trading Analysis for (DNA) - Stock Traders Daily
279,954 Shares in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Purchased by Jacobs Levy Equity Management Inc. - MarketBeat
Ginkgo Bioworks CFO Mark Dmytruk sells $7,146 in stock By Investing.com - Investing.com Australia
Ginkgo Bioworks executive sells $3,182 in stock - Investing.com India
Ginkgo Bioworks CFO Mark Dmytruk sells $7,146 in stock - Investing.com
Ginkgo Bioworks executive sells $3,182 in stock By Investing.com - Investing.com UK
Synthetic Biology Market Forecast: $61.6 Billion by 2029, Growing at 26.1% CAGR - GlobeNewswire Inc.
Concentric By Ginkgo and Texas A&M University Awarded USDA NIFA AFRI Grant to Conduct Genomic Animal Research to Prevent Zoonotic Disease Spillover - Marketscreener.com
Erste Asset Management GmbH Purchases Shares of 500,000 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards? - MSN
PDT Partners LLC Invests $1.20 Million in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Anchorage Capital Group L.L.C. Trims Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
AH Capital Management L.L.C. Trims Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks Advances Collaboration with Merck to Improve Bio - GuruFocus.com
Ginkgo Bioworks Reports Third Quarter 2024 Financial Results - GuruFocus.com
Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Pre - GuruFocus.com
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by Tao Capital Management LP - MarketBeat
US Bancorp DE Decreases Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates - MSN
How To Trade (DNA) - Stock Traders Daily
Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better (NYSE:DNA) - Seeking Alpha
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Short Interest Update - MarketBeat
GSA Capital Partners LLP Has $979,000 Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think - Simply Wall St
Ginkgo Bioworks Holdings Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Ginkgo cancels move to new South Boston lab, exits Cambridge office - MassLive.com
Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q3 2024 Earnings Call Transcript - MSN
Ginkgo Bioworks: Not Enough Progress (NYSE:DNA) - Seeking Alpha
Baillie Gifford & Co. Sells 131,067,285 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks Reports Q3 Growth and Strategic Deals - TipRanks
Ginkgo nixes move to South Boston lab, will exit Cambridge sites. Here's what it means - NBC Boston
Ginkgo nixes move to South Boston lab, will exit Cambridge sites - The Business Journals
Ginkgo Bioworks Reports Third Quarter 2024 Financial Results – Company Announcement - Financial Times
Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing - Marketscreener.com
Insights into Ginkgo Bioworks Holdings's Upcoming Earnings - Benzinga
Ginkgo Bioworks chief accounting officer sells $2,522 in stock - Investing.com India
Ginkgo Bioworks chief accounting officer sells $2,522 in stock By Investing.com - Investing.com Australia
Ginkgo Bioworks Holdings Inc Stock (DNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):